TRESTOLONE Enanthate (MENT long) 100MG/1ML 10ML, ZPHC

Trestolone (MENT) 7α-methyl-19-nortestosterone (An Overview)

Trestolone enanthate, also known as 7α-methyl-19-nortestosterone 17β-enanthate (MENT enanthate), is an androgen and anabolic steroid (AAS) and progestogen which was never marketed
Trestolone is a potent 19-nortestosterone derivative from the same class of steroids as nandrolone and trenbolone, and is an agonist of the androgen receptor, the biological target of androgens such as testosterone.

Anabolic Activity

Trestolone has a myotrophic action that is about 10 times than that of testosterone.

Trestolone has an anabolic to androgenic ratio of 2300:650 (for comparison the rating is 100:100 for testosterone and 500:500 for trenbolone). (6, 10)

Not many other AAS have higher anabolic ratings, one of which known as methyltrienolone (metribolone) is rated at roughly 12000:6000.

It is so potent that it serves as the gold standard for all lab assays that evaluate androgen receptor binding.

Androgen Replacement Therapy

Trestolone is the only AAS currently being produced that seems to be capable of maintaining normal male physiology, including sexual function, in the absence of any testosterone.

Many anecdotal reports suggest that trestolone provides a euthymic and confident feeling.

The molecule is not susceptible to metabolism by the 5-reductase enzyme but does aromatise providing estrogenic effects.

It doesn’t directly impact estradiol. It aromatises into 7α-Methylestradiol (7α-Me-E2).

Researchers discovered that trestolone has anabolic efficacy that is 10 times more than testosterone while also being 12 times more suppressive to the HTPA.

Although it is classed as a progestin, it's shown to have minimal affinity for the progesterone and mineralocorticoid receptors, despite trestolone being a 19-nortestosterone derivative.

Trestolone is a synthetic androgen that inhibits the release of follicle-stimulating hormone and impairs spermatogenesis. Luteinizing hormone is also suppressed, which cuts production of testosterone. The azoospermia and oligospermia are reversible after discontinuation of trestolone. Trestolone has androgenic and anabolic properties and loss of secondary sex characteristics is not seen. Like testosterone, trestolone undergoes enzymatic aromatization to an estrogen. The use of trestolone instead of testosterone for androgen replacement therapy could have health-promoting effects by reducing the occurrence of prostate disease. Trestolone had been in phase II clinical trial for the andropause control. However, this development was discontinued.